title: Neuropeptide systems and new treatments for nicotine addiction.
abstract: The mildly euphoric and cognitive enhancing effects of nicotine play a role in the initiation of smoking, while dysphoria and anxiety associated with smoking cessation contribute to relapse. After the acute withdrawal phase, smoking cues, a few cigarettes (i.e., lapse), and stressors can cause relapse. Human and animal studies have shown that neuropeptides play a critical role in nicotine addiction.
  
  
  
  The goal of this paper is to describe the role of neuropeptide systems in the initiation of nicotine intake, nicotine withdrawal, and the reinstatement of extinguished nicotine seeking.
  
  
  
  The reviewed studies indicate that several drugs that target neuropeptide systems diminish the rewarding effects of nicotine by preventing the activation of dopaminergic systems. Other peptide-based drugs diminish the hyperactivity of brain stress systems and diminish withdrawal-associated symptom severity. Blockade of hypocretin-1 and nociceptin receptors and stimulation of galanin and neurotensin receptors diminishes the rewarding effects of nicotine. Both corticotropin-releasing factor type 1 and kappa-opioid receptor antagonists diminish dysphoria and anxiety-like behavior associated with nicotine withdrawal and inhibit stress-induced reinstatement of nicotine seeking. Furthermore, blockade of vasopressin 1b receptors diminishes dysphoria during nicotine withdrawal, and melanocortin 4 receptor blockade prevents stress-induced reinstatement of nicotine seeking. The role of neuropeptide systems in nicotine-primed and cue-induced reinstatement is largely unexplored, but there is evidence for a role of hypocretin-1 receptors in cue-induced reinstatement of nicotine seeking.
  
  
  
  Drugs that target neuropeptide systems might decrease the euphoric effects of smoking and improve relapse rates by diminishing withdrawal symptoms and improving stress resilience.
authors.affiliation: Department of Psychiatry, University of Florida, 1149 Newell Dr., Gainesville, FL, 32611, USA. awbruijn@ufl.edu.|Department of Neuroscience, University of Florida, Gainesville, FL, USA. awbruijn@ufl.edu.|Center for Addiction Research and Education, University of Florida, Gainesville, FL, USA. awbruijn@ufl.edu.
authors.forename: Adriaan W
authors.initials: AW
authors.lastname: Bruijnzeel
mesh_terms: D000818:Animals; D001007:Anxiety / Q000188:drug therapy / Q000378:metabolism / Q000523:psychology; D003346:Corticotropin-Releasing Hormone / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D009479:Neuropeptides / Q000378:metabolism* / Q000494:pharmacology / Q000627:therapeutic use*; D009538:Nicotine / Q000008:administration & dosage; D017473:Receptors, Opioid, kappa / Q000819:agonists / Q000378:metabolism; D012646:Self Administration; D016540:Smoking Cessation / Q000379:methods* / Q000523:psychology; D013375:Substance Withdrawal Syndrome / Q000188:drug therapy / Q000378:metabolism / Q000523:psychology; D014029:Tobacco Use Disorder / Q000188:drug therapy* / Q000378:metabolism* / Q000523:psychology; D016896:Treatment Outcome
chemical_list: D009479:Neuropeptides; D017473:Receptors, Opioid, kappa; D009538:Nicotine; D003346:Corticotropin-Releasing Hormone
keywords: Anxiety; CRF; Dynorphin; Dysphoria; Hypocretin; Neuropeptide; Nicotine; Relapse; Tobacco; Withdrawal